leo 138559
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 7, 2018 (NCT03514511)
Timeline
Indications
Studied for
Mechanism of action
- Interleukin-22INHIBITOR
IL22 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05923099 | Phase 2 | Sep 20, 2023 | Leo Pharma |
| NCT05470114 | Phase 2 | May 19, 2022 | Leo Pharma |
| NCT05099133 | Phase 1 | Nov 3, 2021 | Leo Pharma |
| NCT04922021 | Phase 2 | Jul 14, 2021 | Leo Pharma |
| NCT03514511 | Phase 1 | May 7, 2018 | Leo Pharma |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 5 | 5 | 2 | 2018 |
1 organizations
Page 1 / 1